Reading Time: 3 minutesAt last year’s Airlie House workshop to develop new ALS/MND Clinical Trial Guidelines the focus was, of course, on MND, but there was also important input
Category: Treatments
Causes and disease mechanisms Clinical Trials Markers of Disease Progression MND Research Research we fund
Lighthouse Project shines a beacon on HERVs and their role in ALS
Reading Time: 3 minutesThere is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to
Reading Time: 5 minutesIt’s been over a month since the announcement by the FDA of their decision to licence edaravone / Radicava for people with MND in the
Reading Time: 4 minutesEach year, the MND Association dedicates the month of June to raising MND awareness. This year, we focus on the eyes – in most people
Reading Time: 2 minutesOn Friday 5 May in America, the FDA, the organisation that approves drugs, announced that they’d granted a licence for the drug known as a
Reading Time: 4 minutesAs well as all the networking, debate and new information being shared, the International Symposium on ALS/MND is also a time to celebrate achievements by
Reading Time: 2 minutesA few months ago we wrote an article about the ALS Clinical Trials Workshop which took place in Virginia, USA. Since then the Guidelines Working
Reading Time: 2 minutesPrevious research in humans and zebrafish has shown that before symptoms arise in MND, early changes occur in the interneurones. This type of nerve cell
Reading Time: 2 minutesDuring the early stages of MND it is proposed that motor neurones are more susceptible to an imbalance of oxygen within the cells, known as
Reading Time: 2 minutesIf you looked at the motor neurones of people with MND down the microscope you would see clumps of a protein called TDP-43. Researchers around